Cargando…

Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience

BACKGROUND: Recent trials involving pirfenidone suggest a beneficial effect in the treatment of idiopathic pulmonary fibrosis (IPF). OBJECTIVE: To report on the efficacy and safety of pirfenidone in the treatment of patients with IPF, at a tertiary care hospital in Saudi Arabia. METHODS: The study i...

Descripción completa

Detalles Bibliográficos
Autor principal: Alhamad, Esam H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286844/
https://www.ncbi.nlm.nih.gov/pubmed/25593606
http://dx.doi.org/10.4103/1817-1737.146866
_version_ 1782351717903368192
author Alhamad, Esam H.
author_facet Alhamad, Esam H.
author_sort Alhamad, Esam H.
collection PubMed
description BACKGROUND: Recent trials involving pirfenidone suggest a beneficial effect in the treatment of idiopathic pulmonary fibrosis (IPF). OBJECTIVE: To report on the efficacy and safety of pirfenidone in the treatment of patients with IPF, at a tertiary care hospital in Saudi Arabia. METHODS: The study included 58 patients with IPF who were evaluated from March 2012 to March 2013. During the study period, 33 patients received pirfenidone, and the remaining patients (n = 25) served as a control group. Baseline clinical characteristics, physiological parameters and the results of a 36-Item Short Form Health Survey (SF-36) were compared between the groups. Furthermore, we compared changes in forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLco), six-minute walk distance (6MWD) and SF-36 for both groups during follow-up. The last follow-up period ended in January 2014. RESULTS: There were no significant differences in baseline clinical characteristics between the groups. Furthermore, we found no differences in FVC, DLco and SF-36 during follow-up (median, 12 months). However, patients receiving pirfenidone treatment were less likely to experience reductions in 6MWD compared with the control group (13% vs. 52%, respectively; P = 0.001). Although adverse events were more frequently reported by the pirfenidone group compared with the control group (85 vs. 56%, respectively; P = 0.015), these patients did not require discontinuation of treatment. CONCLUSION: Pirfenidone treatment preserves functional capacity, as reflected by the 6MWD. Adverse events associated with pirfenidone treatment were generally well tolerated by the patients.
format Online
Article
Text
id pubmed-4286844
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-42868442015-01-15 Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience Alhamad, Esam H. Ann Thorac Med Original Article BACKGROUND: Recent trials involving pirfenidone suggest a beneficial effect in the treatment of idiopathic pulmonary fibrosis (IPF). OBJECTIVE: To report on the efficacy and safety of pirfenidone in the treatment of patients with IPF, at a tertiary care hospital in Saudi Arabia. METHODS: The study included 58 patients with IPF who were evaluated from March 2012 to March 2013. During the study period, 33 patients received pirfenidone, and the remaining patients (n = 25) served as a control group. Baseline clinical characteristics, physiological parameters and the results of a 36-Item Short Form Health Survey (SF-36) were compared between the groups. Furthermore, we compared changes in forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLco), six-minute walk distance (6MWD) and SF-36 for both groups during follow-up. The last follow-up period ended in January 2014. RESULTS: There were no significant differences in baseline clinical characteristics between the groups. Furthermore, we found no differences in FVC, DLco and SF-36 during follow-up (median, 12 months). However, patients receiving pirfenidone treatment were less likely to experience reductions in 6MWD compared with the control group (13% vs. 52%, respectively; P = 0.001). Although adverse events were more frequently reported by the pirfenidone group compared with the control group (85 vs. 56%, respectively; P = 0.015), these patients did not require discontinuation of treatment. CONCLUSION: Pirfenidone treatment preserves functional capacity, as reflected by the 6MWD. Adverse events associated with pirfenidone treatment were generally well tolerated by the patients. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4286844/ /pubmed/25593606 http://dx.doi.org/10.4103/1817-1737.146866 Text en Copyright: © Annals of Thoracic Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Alhamad, Esam H.
Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
title Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
title_full Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
title_fullStr Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
title_full_unstemmed Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
title_short Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
title_sort pirfenidone treatment in idiopathic pulmonary fibrosis: a saudi experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286844/
https://www.ncbi.nlm.nih.gov/pubmed/25593606
http://dx.doi.org/10.4103/1817-1737.146866
work_keys_str_mv AT alhamadesamh pirfenidonetreatmentinidiopathicpulmonaryfibrosisasaudiexperience